Kevin Pantalone
The Cleveland Clinic · Staff
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kevin Pantalone as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:04 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05553145 · The Prevalence of Autoimmune Antibodies in Patients with Type 2 Diabetes Managed by Endocrinology Vs. Primary CareThe Cleveland Clinic · completed · Type 2 Diabetes · principal investigator
- Ph4NCT04538352 · Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2DThe Cleveland Clinic · completed · Type 2 Diabetes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:04 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.Diabetes Obes Metab · 201628 citationsRCR 1.1
- Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial.JAMA Netw Open · 202128 citationsRCR 1.6
- 24 citationsRCR 3.4
- RESULTS OF A 24-WEEK TRIAL OF TECHNOSPHERE INSULIN VERSUS INSULIN ASPART IN TYPE 2 DIABETES.Endocr Pract · 202118 citationsRCR 1.1
- Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.Diabetes Obes Metab · 201817 citationsRCR 0.7
- The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in-person encounters.Obesity (Silver Spring) · 202217 citationsRCR 1.5
- A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment.Diabetes Care · 202114 citationsRCR 0.8
- The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.Diabetes Obes Metab · 202313 citationsRCR 1.2
- De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).Diabetes Obes Metab · 20258 citationsRCR 1.8
- Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.Diabetes Res Clin Pract · 20244 citationsRCR 0.4